• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Japan approves Bristol Myers Squibb’s B-cell lymphoma therapy pharmaceutical-business-review
    March 31, 2021
    Bristol Myers Squibb has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for its Breyanzi (lisocabtagene maraleucel; liso-cel) to treat patients suffering from relapsed or refractory (R/R) large B-cell lymphoma (LBCL) and R/R ...
  • FDA Approves BMS CAR-T Cell Therapy contractpharma
    February 10, 2021
    Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory large B-cell lymphoma.
  • Gilead’s CAR T therapy Yescarta shows potential in new indication pharmatimes
    December 10, 2020
    Gilead’s Yescarta has scored some promising interim results from a phase II study evaluating the chimeric antigen receptor (CAR) T therapy as a first-line treatment for high-risk large B-cell lymphoma (LBCL) patients.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service